Ibrance US Health Economics & Outcomes Research Director


To support the strategic goals of the Oncology Business by driving optimal patient access for Ibrance and pipeline breast cancer medicines.

This role directly impacts the ability to achieve business objectives on in the US by providing strategic guidance and robust evidence development relevant to achieve optimal US patient access by demonstrating the value of our breast cancer medicines. The HEOR Director will be responsible for independently leading the US HEOR evidence generation strategy, including oversight and development of evidence generation and dissemination of technical deliverables and tools that support the value of Ibrance. For pipeline assets, the HEOR Director will be responsible in developing launch deliverables to key external stakeholders. This role will be predominantly focused on supporting the US business.

This position will function with a 'One Patient & Health Impact' mindset and will work in a closely aligned fashion with the Breast PHI team members to ensure there is a single and coordinated view on strategy and delivery from the Breast PHI team to the oncology business. This position reports to the Oncology Breast ITL.

  • Lead the development of Health Economics & Outcomes Research (HEOR) strategy to support the value of Ibrance and pipeline breast assets in the Oncology Business Unit (BU) in close partnership with the cross-functional matrix team.
  • Lead the design and execution of HEOR studies and projects (including Non-Interventional Studies, registries, burden of illness studies, epidemiology studies etc.) for the US market in alignment with the global O&E strategy and US cross functional partners.
  • Incorporate humanistic and economic endpoints into clinical trials across all phases of product development to build comprehensive trial-based evidence in line with overall medical strategy for the assets and to ensure global reimbursement and access requirements. Provide strategic input in the selection of relevant patient population and comparators within clinical trials to enable successful negotiations, reimbursement, and appropriate patient access with global payer and regulatory decision makers.
  • Development and validation of new Patient Reported Outcomes measures as appropriate for inclusion across clinical trials, registries, and prospective real world studies
  • Identify opportunities to partner with Oncology BU external customers to conduct HEOR projects in support of asset strategies
  • Lead the timely development of launch and post launch deliverables including global value dossiers (GVD and AMCP), evidence blueprints, economic models, and innovative tools to successfully support US launch and post-launch reimbursement and access requirements in conjunction with the regions/countries.
  • Lead the coordination of input from local country/regional teams on evidence needs and ensure that the input is appropriately incorporated to develop and integrated evidence strategy to support global market access needs at launch and through lifecycle.
  • Develop strategic partnerships and research collaborations with key external experts, healthcare policy makers, payers, and various academic and community oncology settings to support asset strategies.
  • Provide strategic guidance and content guidance in reimbursement (re)negotiations for Pfizer products.
  • Lead the development of appropriate data dissemination plans and communicate evidence generated via publications and conference presentations.
  • Partner with internal stakeholders to ensure appropriate customer facing dissemination of HEOR materials per FDA guidance and internal SOPs


Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
  • Clinical degree (e.g. PharmD, MD) or Masters degree (MSc, MPH) in health services research, public health, epidemiology, or health economics with a preferred Doctoral degree (PhD, DrPH, ScD) in health services research, public health, epidemiology, or health economics.
  • Minimum 10 years' experience in health outcomes and related fields, 5 of which are as part of global health economics and/or outcomes research teams in a pharmaceutical company.
  • Strong working knowledge of the technical and methodological aspects of registries and observational study design, implementation, analysis and interpretation. Capable of independently managing complex registry and non-interventional study projects.

  • In depth understanding of Pharmacoeconomics and Health-related Quality of Life
  • Knowledge and experience in the oncology therapeutic area is preferred
  • Strong understanding of the US healthcare market is desirable
  • Experience with HTA organizations such as ICER and/or global organizations such as NICE, SMC, PBAC is desirable
  • Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers
  • Excellent oral and written English communication skills required
  • Strong project management abilities (contracting, budgeting, vendor management) essential. Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities
  • Ability to influence key members of medical and commercial teams constructively and without conflict
  • Skilled in functioning within a matrix organization where managing through influence is required
  • Organized and detail oriented with the ability to anticipate needs and to work proactively to prioritize & address/resolve
  • Change oriented, comfortable responding to unexpected demands with tight timelines; team player

Other Job Details:

Last Date to Apply for Job: December 17th, 2021

Additional Location Information: New York, NY; US - Remote; Europe - Remote


Pfizer requires all U.S. new hires to be fully vaccinated for COVID-19 prior to the first date of employment. As required by applicable law, Pfizer will consider requests for Reasonable Accommodations.

Sunshine Act

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.

EEO & Employment Eligibility

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.

Market Access